Kissei Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3240600001
JPY
4,585.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

46.3 k

Shareholding (Sep 2013)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 89.25

 
2

Low Debt Company with Strong Long Term Fundamental Strength

 
3

Flat results in Jun 25

4

With ROE of 6.96%, it has a very attractive valuation with a 0.96 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 217,756 Million (Small Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.01%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

7.16%

stock-summary
Price to Book

1.05

Revenue and Profits:
Net Sales:
22,191 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,520 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.77%
0%
0.77%
6 Months
9.43%
0%
9.43%
1 Year
28.43%
0%
28.43%
2 Years
46.49%
0%
46.49%
3 Years
83.69%
0%
83.69%
4 Years
114.25%
0%
114.25%
5 Years
111.97%
0%
111.97%

Kissei Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.91%
EBIT Growth (5y)
25.47%
EBIT to Interest (avg)
89.25
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.37
Tax Ratio
23.28%
Dividend Payout Ratio
36.47%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
1.34%
ROE (avg)
5.25%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.96
EV to EBIT
26.65
EV to EBITDA
14.81
EV to Capital Employed
0.95
EV to Sales
1.74
PEG Ratio
0.39
Dividend Yield
0.01%
ROCE (Latest)
3.57%
ROE (Latest)
6.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2013stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 4.85% vs 9.58% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.11% vs 23.53% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22,191.00",
          "val2": "21,164.00",
          "chgp": "4.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,197.00",
          "val2": "3,279.00",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.00",
          "val2": "4.00",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "116.00",
          "val2": "-70.00",
          "chgp": "265.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,520.00",
          "val2": "4,105.00",
          "chgp": "10.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "95.00%",
          "val2": "102.00%",
          "chgp": "-0.70%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 16.87% vs 11.98% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 6.08% vs 6.16% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "88,330.00",
          "val2": "75,579.00",
          "chgp": "16.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,570.00",
          "val2": "8,271.00",
          "chgp": "27.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "21.00",
          "val2": "18.00",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3,203.00",
          "val2": "306.00",
          "chgp": "-1,146.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11,975.00",
          "val2": "11,289.00",
          "chgp": "6.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "65.40%",
          "val2": "53.10%",
          "chgp": "1.23%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
22,191.00
21,164.00
4.85%
Operating Profit (PBDIT) excl Other Income
3,197.00
3,279.00
-2.50%
Interest
6.00
4.00
50.00%
Exceptional Items
116.00
-70.00
265.71%
Consolidate Net Profit
4,520.00
4,105.00
10.11%
Operating Profit Margin (Excl OI)
95.00%
102.00%
-0.70%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 4.85% vs 9.58% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 10.11% vs 23.53% in Jun 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
88,330.00
75,579.00
16.87%
Operating Profit (PBDIT) excl Other Income
10,570.00
8,271.00
27.80%
Interest
21.00
18.00
16.67%
Exceptional Items
-3,203.00
306.00
-1,146.73%
Consolidate Net Profit
11,975.00
11,289.00
6.08%
Operating Profit Margin (Excl OI)
65.40%
53.10%
1.23%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 16.87% vs 11.98% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 6.08% vs 6.16% in Mar 2024

stock-summaryCompany CV
About Kissei Pharmaceutical Co., Ltd. stock-summary
stock-summary
Kissei Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available